Cardiff Oncology (CRDF) EBT (2011 - 2026)
Cardiff Oncology (CRDF) posted EBT of -$64.5 million for Q4 2025, down 436.52% sequentially from -$12.0 million in Q3 2025, and down 174.91% YoY from $86.1 million in Q4 2024.
Cardiff Oncology (CRDF) EBT (2011 - 2026) Analysis & Trends
Cardiff Oncology has reported EBT for 15 years, with the latest figure at -$64.5 million in Q4 2025.
- Quarterly EBT fell 174.91% year-over-year to -$64.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$113.3 million (down 44.29% YoY) and the FY2025 annual result came in at -$103.1 million, down 9.9% from the prior year.
- EBT eased to -$64.5 million in Q4 2025 per CRDF's latest filing, from -$12.0 million in the prior quarter.
- Over five years, EBT peaked at -$9.6 million in Q4 2022 and troughed at -$64.5 million in Q4 2025.
- A 5-year average of -$19.1 million and a median of -$14.4 million in 2021 frame the typical range for EBT.
- The sharpest annual moves came in 2023 and 2024: EBT tumbled 406.58% in 2023, then jumped 51.64% in 2024.
- Over 5 years, EBT stood at -$9.7 million in 2021, then increased by 1.81% to -$9.6 million in 2022, then sank by 406.58% to -$48.5 million in 2023, then surged by 51.64% to -$23.5 million in 2024, then tumbled by 174.91% to -$64.5 million in 2025.
- According to Business Quant data, EBT over the past three periods registered -$64.5 million, -$12.0 million, and -$18.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 541.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -767.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 312.46 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 177.81 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -264.70 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -11.37 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Cardiff Oncology | 60.21 Mn | 60.21 Mn | - | -9.23 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -9.30 Mn |
| Dec 31, 2025 | -64.48 Mn |
| Sep 30, 2025 | -12.02 Mn |
| Jun 30, 2025 | -18.70 Mn |
| Mar 31, 2025 | -18.15 Mn |
| Dec 31, 2024 | -23.45 Mn |
| Sep 30, 2024 | -14.40 Mn |
| Jun 30, 2024 | -12.91 Mn |
| Mar 31, 2024 | -27.79 Mn |
| Dec 31, 2023 | -48.50 Mn |
| Sep 30, 2023 | -10.17 Mn |
| Jun 30, 2023 | -13.92 Mn |
| Mar 31, 2023 | -12.43 Mn |
| Dec 31, 2022 | -9.57 Mn |
| Sep 30, 2022 | -9.79 Mn |
| Jun 30, 2022 | -13.94 Mn |
| Mar 31, 2022 | -14.75 Mn |
| Dec 31, 2021 | -9.75 Mn |
| Sep 30, 2021 | -14.52 Mn |
| Jun 30, 2021 | -14.33 Mn |